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Abstract
Background: Maternal malaria is associated with serious adverse pregnancy outcomes. One recommended means of
preventing malaria during pregnancy is intermittent preventive therapy (IPTp) with sulfadoxine/pyrimethamine (SP). We
sought to identify determinants of preventive use of SP during pregnancy among recently pregnant women in Uganda.
Additionally, we characterized the timing of and indications for the administration of SP at antenatal care (ANC) visits and
missed opportunities for SP administration.
Methodology/Principal Findings: Utilizing a population-based random sample, we interviewed 500 women living in Jinja,
Uganda who had been pregnant in the past year. Thirty-eight percent (192/500) of women received SP for the treatment of
malaria and were excluded from the analysis of IPTp-SP. Of the remaining women, 275 (89.3%) reported at least two ANC
visits after the first trimester and had an opportunity to receive IPTp-SP according to the Ugandan guidelines, but only 86
(31.3%) of these women received a full two-dose course of IPTp. The remaining 189 (68.7%) women missed one or more
doses of IPTp-SP. Among the 168 women that were offered IPTp, 164 (97.6%) of them took the dose of SP.
Conclusions/Significance: Use of IPTp in Uganda was found to be far below target levels. Our results suggest that women
will take SP for IPTp if it is offered during an ANC visit. Missed opportunities to administer IPTp-SP during ANC were
common in our study, suggesting provider-level improvements are needed.
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Introduction
Approximately 30 million pregnancies occur each year in
malaria endemic areas of sub-Saharan Africa [1]. Severe
complications of malaria during pregnancy include cerebral
malaria, maternal anemia, and maternal mortality, which tend
to be more frequent during epidemics and among primigravid
and/or immunocompromised pregnant women [2,3]. Complica-
tions affecting the fetus or newborn may arise from either clinical
malaria or asymptomatic parasitemia during pregnancy and
include miscarriage, stillbirth, low birthweight, preterm delivery,
and neonatal mortality [2,3].
The World Health Organization (WHO) guidelines for the
prevention of malaria during pregnancy include 1) use of
intermittent preventive treatment during pregnancy (IPTp) with
sulfadoxine/pyrimethamine (SP); and 2) sleeping under an
insecticide-treated bed net (ITN) [4]. IPTp-SP is defined as
provision of treatment doses of SP to asymptomatic individuals
living in malaria endemic regions, regardless of malaria parasit-
emia status, and the current recommendation is that at least 2
doses of SP should be administered after the first trimester during
antenatal care (ANC) [5].
Use of IPTp is estimated to reduce the occurrence of low
birthweight by 42%, neonatal death by 38%, placental malaria by
65%, and antenatal parasitemia by 26% [6]. Even in areas where
SP monotherapy for symptomatic malaria results in up to 25%
treatment failures, 2 doses of IPTp with SP continued to provide
considerable benefit to HIV-negative semi-immune pregnant
women [7]. Despite the effectiveness of IPTp, and the nearly
universal adoption of a national IPTp policy among malaria
endemic countries [8], its use remains relatively uncommon in
sub-Saharan Africa. Furthermore, data on IPTp coverage from
national surveys remain limited. During 2007-2008, only 9 high-
burden countries had national survey data on IPTp, resulting in
only 20% of pregnant women who received 2 or more doses of
IPTp [8]. In Uganda 37% of women reported receiving at least
one dose of SP to prevent malaria during pregnancy, and only 18
percent received two or more doses [9].
Demographic factors associated with use of IPTp have been
evaluated in several studies [10,11,12,13,14], although associations
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with education and age have been inconsistent across studies
[10,11,14,15]. A lack of association between IPTp use and socio-
demographic factors household wealth, knowledge of malaria,
travel times to the ANC clinic and the number of ANC visits has
been reported [10,11,12,14,15]. Operational barriers affecting
uptake of IPTp include: 1) imprecision in the estimation of
gestational age leading to missed doses [16,17]; 2) confusion
regarding the timing of doses and/or the recommended number of
SP doses [16,17,18]; 3) late or no antenatal care attendance
[16,17,19]; and lack of potable water and/or drinking cups (for
directly observed SP administration) [16,17,18].
Utilizing a population-based sample, we sought to describe the
use of SP during pregnancy in one health district in Uganda and to
identify determinants of use of IPTp. Additionally, we sought to
describe the administration practices of SP during visits to the
ANC clinic.
Methods
Selection of study participants
Between November, 2008 and January, 2009 a simple random
sample of 500 female residents of Kibibi and Namizi parishes in
Budondo-sub county of Jinja District, Uganda was invited to
participate in a home-based interview to ascertain use of ITNs and
SP during pregnancy, as well as possible factors associated with
use. Interviews were conducted using a structured pre-tested
questionnaire adapted from the conceptual framework proposed
by Ribera et al. [20]. Women between the ages of 15 and 49 years
who had a pregnancy within the past 12 months that lasted until at
least the third trimester, regardless of pregnancy outcome, were
eligible to participate. Due to the cross-sectional design of the
study, current pregnancies were excluded to ensure equal
opportunity among all participants to have received IPTp during
their most recent pregnancy. Budondo-sub county of Jinja District
was selected as the field site based on the availability of a recently
completed census in November 2008, allowing for a population-
based simple random sample to be selected. Namizi and Kibibi
parishes are comprised of 16 rural and peri-urban villages, with a
combined population of 21,681, of whom 4,654 were females aged
15–49 years, and 867 of these women reported having been
pregnant in the previous 12 months.
Study site
Jinja district is a peri-urban area where malaria is considered
meso-endemic, with a relatively low transmission intensity; the
average annual entomological inoculation rate is 6 infective bites
per person per year [21].
Each parish has one public health center; Kibibi has a level II
facility and Namizi a level IV facility. The administration policy of
IPTp and the frequency of stock-outs of SP at the study clinics
were assessed prior to the start of the study. Stock-outs of SP
during the study period were uncommon (Namizi and Kibibi
health centers, personal communication). While the Ugandan
guidelines specify IPTp with SP should be taken as directly
observed therapy (DOT), this is not consistently implemented in
the study clinics due to lack of access to clean water and cups.
Administration of the survey
For each ANC visit the woman attended, we ascertained if SP
was offered or not and categorized her experience as 1) having
received SP; 2) out of stock of SP, the woman was told to buy it on
her own or return to ANC later to receive it; 3) asked to buy SP
from the ANC; 4) the ANC never mentioned SP, or 5) SP was
offered, but the woman declined to use it.
To facilitate recall, a pregnancy history calendar was generated
for each woman and used to record episodes of self-reported
malaria, any use of SP or other antimalarials during pregnancy,
and ANC visits. Additionally, women were shown photographs of
SP packaging and the corresponding tablets for the most common
formulations of SP available in the area. Self-reported SP use was
compared with SP administration as recorded on antenatal cards
for the subset of women who had retained the cards.
Data management
IPTp with SP was defined as a complete 2-dose course of SP
administered after the first trimester [9,22,23,24,25], if the participant
believed the SP was used for the prevention of malaria. The analysis
of IPTp was restricted to those participants with at least two
qualifying ANC visits after the first trimester who had the opportunity
to receive a complete course of IPTp. The indication for the use of SP
(treatment or prevention) was based on self-report from the woman
by asking her if she believed she was sick with malaria for each of the
doses of SP that she received. Women who reported receiving SP for
the treatment of malaria symptoms were excluded from the analysis
of IPTp-SP for the following reasons: 1) determinants of use of
treatment doses among women with symptoms suggestive of malaria
are likely to be different than those of preventive doses among
asymptomatic women; and 2) women who received a therapeutic
dose of SP administered in concordance with the IPTp schedule
would be unlikely to receive the recommended two or more
preventive doses of SP. The Ugandan IPTp guidelines recommend
that SP should not be given: during the first trimester of pregnancy,
less than 4 weeks between doses, to women with a history of allergies
to sulfa drugs, to women concurrently using cotrimoxazole, or to
women with symptomatic malaria [26].
IPTp-SP was categorized as a full course: a complete 2-dose
course of IPTp administered after the first trimester; partial course:
only 1 dose after the first trimester; or none: a) 0 doses in the after
the 1st trimester.
Statistical analysis
Analyses were performed using Stata version 11.0 (College
Station, Texas, USA). A 7-point composite variable was generated
to summarize each woman’s knowledge of malaria, and a 4-point
composite variable summarized her knowledge of SP safety.
Principal components analysis was used to calculate the household
wealth index, a standardized composite measure combining the
cumulative living standard of a household and is based on a
household’s ownership of selected assets, such as televisions and
bicycles, materials used for housing construction, and types of
water access and sanitation facilities [27]. Relative risk regression
was used to determine the association between exposures of
interest and receipt of a full-course of IPTp-SP [28,29]. Risk
estimates were adjusted for the number of ANC visits, however,
small numbers precluded further adjustments.
Ethics statement
The study was approved by theMakerere University Research and
Ethics Committee, the Uganda National Council for Science and
Technology, and the University of Washington, Human Subjects
Division. All participants provided written informed consent.
Results
Between November 2008 and January 2009 we visited 629
households to identify 500 eligible women (Figure 1), none of
whom declined to participate. Seven of the index pregnancies
ended in stillbirth. Use of ANC was nearly ubiquitous with 94.2%
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of women reporting 2 or more visits, and 90.8% reporting 2 or
more ANC visits after the first trimester. Only 34.0% completed
the recommended 4 or more visits during pregnancy. Most of the
women delivered in a health facility (73.4%), and 16.2% delivered
at home. Symptomatic malaria during pregnancy was self-
reported by 66.8% of the participants. The characteristics of
women with at least two qualifying ANC visits were similar to
those of the entire cohort and are shown in Table 1.
Concordance of self-reported SP and ANC cards
Twenty-seven percent of women (136/500) had an ANC card
available. The number of SP doses used for any reason (treatment
or prevention) was listed on 106 of the cards and ranged from 0 to
4 doses. The concordance between self-reported SP doses and
ANC card was high (Pearson’s rho = 0.93).
Reasons for SP use among women who had an ANC card
available were as follows: prevention only 40.1%, any treatment
use 36.8%, or no use 22.6%. Excluding women who received SP
for treatment, the concordance between self-reported SP doses
and ANC card remained high (Pearson’s rho = 0.95).
Any SP use during pregnancy
Seventy-three percent of participants (365/500) reported having
taken a dose of SP at least once during pregnancy for prevention
or treatment of malaria; 28.2% (n= 141) reported taking 1 dose
and 44.8% (n= 224) reported taking 2 or more doses. Among SP
users, 173 (47.4%) used SP for prevention only (believed they did
not have symptomatic malaria each time they took SP), 132
(36.2%) used SP for treatment only (believed they did have
symptomatic malaria each time they took SP), and the remaining
60 (16.4%) used SP as both treatment and prevention.
Administration of SP by the health facility
Among all participants, 90.8% (n= 454) of them had at least
two ANC visits in which a full course of IPT-SP could have been
administered according to the Ugandan guidelines. However, SP
was not administered in accordance with recommendations in
81.1% (n= 368) of these women: 41.6% (n= 189) missed an
opportunity to receive the recommended 2 preventive doses
during pregnancy (0 doses: n = 110; 1 dose: n = 79), and 39.4%
(n= 179) believed they received SP as treatment for an episode of
malaria during pregnancy.
IPTp-SP use during pregnancy among women with 2 or
more qualifying ANC visits
While the proportion of women who received 2 or more doses
of SP was 44.8% (224/500), only 31.3% (86/275) of women
received a full 2-dose course of IPTp-SP according to the
Ugandan policy for the prevention of malaria (Table 2). A partial
course of IPTp was used among 28.7% of women. The number of
women receiving no doses of SP in the 2nd and/or 3rd trimesters
despite qualifying ANC visits was 40.0%.
Among the 168 women that were offered IPTp, 164 (97.6%) of
them took the dose of SP. Only 2 women used SP for prevention
despite never being offered it during an ANC visit, and only 4
women who were offered SP for prevention during an ANC visit
chose not to use it.
Predictors of IPTp-SP among women with 2 or more
qualifying ANC visits
Individual-level factors associated with receipt of a full-course of
IPTp-SP compared to no doses were assessed among women with
at least 2 qualifying ANC visits controlling for the total number of
ANC visits (Table 3). Receipt of a full-course of IPTp-SP was
relatively more common among women living in a rural village
compared to a peri-urban area (RR: 2.73; 95% CI: 1.50, 4.99),
those with the capacity to decide if SP should be used during
pregnancy (RR: 2.28; 95% CI: 1.48, 3.49), and those who were
less knowledgeable about the safety of SP use during pregnancy
Figure 1. Eligibility and participation of study participants. *Reflects completed pregnancies lasting at least until the beginning of the 3rd
trimester, regardless of pregnancy outcome. **Most recent pregnancy occurred more than 12 months from the interview date due to a lag time
between the start of the census and the start of the study.
doi:10.1371/journal.pone.0015066.g001
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(RR: 1.87; 95% CI: 1.40, 2.49). Furthermore, women with lower
educational attainment were more likely to receive a full-course
(RR: 1.56; 95% CI: 1.03, 2.38), as were women living more than
30 minutes walking distance to the ANC clinic (RR: 2.06; 95% CI:
1.23, 3.46). No differences were found between other socio-
demographic factors, pregnancy history, or socio-cultural factors.
Individual-level factors associated with receipt of a full-course
compared to a partial-course of IPTp-SP were assessed among
women with at least 2 qualifying ANC visits controlling for the total
number of ANC visits. Women receiving a full-course of IPTp-SP
had slightly less knowledge of malaria and SP compared to women
receiving a partial-course (data not shown). No differences were found
between these groups and the remaining socio-demographic factors,
pregnancy history, and socio-cultural factors (data not shown).
Among women who received a partial course of IPTp-SP, the main
reasons given for not having taken a full-course of IPTp were ‘‘I didn’t
know about it’’ (49.3%), and ‘‘it wasn’t offered’’ (34.7%).
Discussion
In the present study of 500 recently pregnant women in Jinja,
Uganda, less than one-third of women received a full-course of IPTp-
SP despite the high utilization of ANC in this cohort. While IPTp is a
relatively simple intervention to administer, missed opportunities
were common in our study. This is one of only a few studies to
investigate correlates of IPTp use from the perspective of the user.
Our definition of IPTp-SP was restricted to preventive doses of
SP administered after the first trimester of pregnancy, in accordance
with the IPTp policy guidelines. Including treatment doses of SP
taken after the first trimester in the analysis of IPTp would lead to an
overestimate of the prevalence of IPTp due to the large proportion
of women receiving SP for the treatment of malaria. The means of
assessment of uptake of IPTp has varied across studies and
disaggregation by presence or absence of symptomatic malaria
has not been standard practice. Some studies explicitly stated that
preventive doses of SP were presumptive (when the woman was not
sick with malaria) [10,30,31,32], although timing of doses were not
specified. Other studies referred only to the number of doses of SP
without reference to the womans’ clinical state [11,14,33,34,35].
One study defined IPTp based on number of doses of SP given at
ANC irrespective of signs or symptoms of malaria [18]. Appropriate
IPTp has been defined in one study based on the timing of SP use
during pregnancy (at least one dose in the 2nd trimester, and at least
one dose in the 3rd trimester), although this study did not indicate if
doses were restricted to preventive use [12], while another study
defined IPTp based on 3 presumptive doses starting after 16
gestational weeks, with subsequent doses being indicated at intervals
of 1 month or more [16]. Surveys such as the DHS ask, ‘‘During this
pregnancy, did you take any drugs to keep you from getting
malaria?’’, and only if the women answer ‘‘yes’’ will they specifically
be asked if they took SP, and the number of times. Standardizing the
approach to defining IPTp with SP, or other drugs, would facilitate
measurement of utilization across studies.
Among women in our study, the predominant factor predicting
preventive use of SP during pregnancy was being offered IPTp
Table 1. Characteristics of the study population.
Characteristic
All women
interviewed
n=500
Women with
at least 2
qualifying
ANC visits
n=2751
Age (years); mean (sd) 25.5 (6.2) 25.4 (6.3)
#18 years 50 (10.0) 30 (10.9)
19–24 years 204 (40.8) 114 (41.4)
25–34 years 182 (36.4) 96 (34.9)
$35 years 64 (12.8) 35 (12.7)
Married; n (%) 451 (90.2) 247 (89.8)
Education; n (%)
None 34 (6.8) 14 (5.1)
Primary 350 (70.0) 197 (71.6)
Secondary/Postsecondary 116 (23.2) 64 (23.3)
Religion; n (%)
Christian-based 305 (61.0) 160 (58.2)
Muslim 195 (39.0) 115 (41.8)
Village type; n (%)
Rural 372 (74.4) 213 (77.4)
Peri-Urban 128 (25.6) 62 (22.6)
Number of births; mean (sd) 3.9 (2.6) 3.8 (2.6)
Knowledge of malaria score; n (%)
High 292 (58.4) 162 (58.9)
Low 208 (41.6) 113 (41.1)
Belief SP is safe during pregnancy; n (%) 248 (49.7) 122 (44.4)
Knowledge of SP safety score; n (%)
High 447 (89.4) 240 (87.3)
Low 53 (10.6) 35 (12.7)
Who decides if SP is used during
pregnancy? n (%)
Respondent 159 (31.8) 90 (32.7)
Husband/partner 25 (5.0) 15 (5.4)
Respondent and husband jointly 130 (26.0) 84 (30.6)
Someone else 186 (37.2) 86 (31.3)
Most important influence to use SP; n (%)
Given free at ANC 97 (19.4) 53 (19.3)
Recommended by a doctor or nurse 341 (68.2) 193 (70.2)
Ad on radio or poster 23 (4.6) 12 (4.4)
Hearing from other pregnant women 39 (7.8) 17 (6.2)
1(n = 275): Excludes women without 2 qualifying ANC visits in the 2nd and 3rd
trimester (n = 46), women using SP for the treatment of malaria (n = 179).
doi:10.1371/journal.pone.0015066.t001
Table 2. Doses of IPTp-SP taken during pregnancy among
women with 2 or more qualifying ANC visits.
Number of doses of SP-IPT1 n (%)
Full course 86 (31.3)
$2 doses in 2nd AND 3rd trimesters 64
$2 doses in 2nd or 3rd trimesters 22
Partial course 79 (28.7)
,2 doses in 2nd or 3rd trimesters, no incorrect doses 73
,2 doses in 2nd or 3rd trimesters, plus 1st trimester use 6
None 110 (40.0)
0 doses 109
1st trimester use only 1
1(n = 275): Excludes women without qualifying ANC visits in the 2nd and 3rd
trimester (n = 46), women using SP for the treatment of malaria (n = 179).
doi:10.1371/journal.pone.0015066.t002
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during an ANC visit. Stock-outs of SP were seldom responsible for
missed doses; only during 5.6% of ANC visits (61/1084) was a
woman told that the clinic was out of stock of SP and they should
purchase it on their own. The majority of women were either
offered SP and used it, or SP was never mentioned during their
visit and they did not use it. Small numbers precluded an
assessment of individual-level factors associated with use of IPTp
independent of being offered SP for prevention. Only 2 women
used SP for prevention despite never being offered it during an
ANC visit, and only 4 women who were offered SP for prevention
during an ANC visit chose not to use it. Our results suggest that
use of IPTp was low among women in our study because providers
failed to offer SP. These findings highlight the importance that
health workers play in delivering IPTp and the need to explore
barriers to offering this therapy.
To our knowledge, this variable ‘‘being offered’’ has only been
assessed in two studies, both of which reported not being offered
SP during ANC was the reason for not completing a full-course of
IPTp-SP [15,36]. Confusion among health care workers regarding
the timing of doses and/or the number of doses has been reported
in several studies, and may be the underlying reason a dose of SP
was not offered during a qualifying visit [16,17,18]. Improvements
in the administration of IPTp following focused training of health
care workers was demonstrated in one intervention study [18]
supporting the notion that unclear guidelines are adversely
contributing to the uptake of IPTp. Further uncertainty regarding
administration of IPTp may also be related to an omission in the
WHO IPTp guidelines regarding how treatment for symptomatic
malaria (either presumptively treated or laboratory confirmed)
might alter eligibility for or timing of the IPTp. The majority of
women in our study had complex histories related to self-reported
malaria, and use of antimalarials for treatment of malaria was high
during the index pregnancy. This led to difficulties in classifying a
woman’s SP use during pregnancy as being consistent or
inconsistent with the recommended guidelines. For example, if a
woman is sick with malaria-like symptoms and receives SP as a
treatment dose in the 2nd or 3rd trimester, the guidelines did not
specify if this dose should be counted as IPTp. Or, if a woman is
sick with malaria-like symptoms and treated for confirmed or
presumed malaria with non-SP antimalarials, the guidelines did
not specify when she should receive SP as presumptive treatment.
Table 3. Individual-level factors associated with full
adherence to IPTp-SP recommendations among women with
at least 2 qualifying ANC visits.
Characteristic
Full
course
n=86
No
doses
n=110 aRR (95% CI)
Age (years); n (%)
#18 years 10 (41.7) 14 (58.3) 0.77 (0.47, 1.26)
19–24 years 39 (52.7) 35 (47.3) Reference
25–34 years 25 (36.8) 43 (63.2) 0.74 (0.51, 1.08)
$35 years 12 (40.0) 18 (60.0) 0.76 (0.46, 1.24)
Marital status; n (%)
Single 8 (36.4) 14 (63.6) 0.97 (0.55, 1.70)
Married 78 (44.8) 96 (55.2) Reference
Education; n (%)
None 2 (22.2) 7 (77.8) 0.79 (0.22, 2.85)
Primary 68 (49.6) 69 (50.4) 1.56 (1.03, 2.38)
Secondary/Postsecondary 16 (32.0) 34 (68.0) Reference
Religion; n (%)
Christian 53 (43.4) 69 (56.6) Reference
Muslim 33 (44.6) 41 (55.4) 1.04 (0.76, 1.45)
Parish; n (%)
Kibibi 34 (41.5) 48 (58.5) Reference
Namizi 52 (45.6) 62 (54.4) 1.07 (0.78, 1.47)
Village type; n (%)
Rural 77 (51.7) 72 (48.3) 2.73 (1.50, 4.99)
Peri-Urban 9 (19.1) 38 (80.9) Reference
Household wealth index; n (%)
1 (Most poor) 23 (57.5) 17 (42.5) 1.25 (0.78, 2.00)
2 13 (38.2) 21 (61.8) 0.85 (0.47, 1.53)
3 20 (45.4) 24 (54.6) 0.90 (0.53, 1.51)
4 14 (31.1) 31 (68.9) 0.67 (0.37, 1.21)
5 (Least poor) 13 (46.4) 15 (53.6) Reference
Number of births; n (%)
1 19 (43.2) 25 (56.8) 1.28 (0.78, 2.09)
2–3 32 (54.2) 27 (45.8) 1.50 (0.96, 2.32)
4–5 17 (42.5) 23 (57.5) 1.25 (0.74, 2.09)
$6 18 (34.0) 35 (66.0) Reference
Knowledge of malaria score;
n (%)
High 47 (43.9) 60 (56.1) 1.11 (0.81 1.53)
Low 39 (43.8) 50 (56.2) Reference)
Knowledge of SP safety
score; n (%)
High 69 (39.9) 104 (60.1) Reference
Low 17 (73.9) 6 (26.1) 1.87 (1.40, 2.49)
Who decides if SP should
be used during pregnancy?
n (%)
Respondent or Respondent
and husband jointly
68 (55.7) 54 (44.3) 2.28 (1.48, 3.49)
Husband/partner or
someone else
18 (24.3) 56 (75.7) Reference
Who controls money for
healthcare in your household
Characteristic
Full
course
n=86
No
doses
n=110 aRR (95% CI)
Respondent and husband jointly 37 (44.0) 47 (56.0) 1.02 (0.74, 1.39)
Husband/partner or someone
else
49 (43.7) 63 (56.3) Reference
Average time to walk to ANC
(minutes); n (%)
#30 11 (24.4) 34 (75.6) Reference
$30 75 (49.7) 76 (50.3) 2.06 (1.23, 3.45)
Average time to wait for ANC
(minutes); n (%)
#30 37 (45.1) 45 (54.9) Reference
.30 49 (43.0) 65 (57.0) 1.08 (0.79, 1.47)
aRR: Adjusted for total number of ANC visits.
This analysis excludes any women who used SP for treatment of malaria.
doi:10.1371/journal.pone.0015066.t003
Table 3. cont.
Determinants of Use of IPTp
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e15066
We were unable to evaluate why health care workers offered a
full- or partial-course of IPTp-SP to some women, and failed to
offer IPTp-SP to forty percent of the remaining participants with
at least two qualifying visits. While we were able to explore
individual-level predictors for having received a full-course of
IPTp-SP compared to no doses among women with at least two
qualifying ANC visits, these exposures were a poor proxy for
health care worker behavior. In addition to ANC attendance,
individual-level factors associated with having received a full-
course of IPTp included living in a rural residence, being less
knowledgeable about the safety of SP use during pregnancy,
having less education, living further from the ANC clinic, and the
respondent being the household member who decides if SP will be
used during pregnancy. The findings across the various studies,
including ours, are not consistent with regard to these potential
influences on receipt of IPTp [10,11,12,14].
Similar to our findings, the primary reasons for not completing a
full 2-dose course of IPTp among women who had received only 1
dose included not being given IPTp from the ANC and lack of
awareness about the 2-dose schedule [36]. The lack of individual-
level factors strongly associated with use of IPTp-SP in the literature,
combined with our finding of the importance of having been offered
SP during an ANC visit, suggest that factors related to health-care
provider behavior are more influential in the uptake of IPTp than
most measurable individual-level factors. Evaluations of health care
provider practices regarding administration of IPTp are needed to
measure the extent of the problem and develop targeted interven-
tions at improving access to IPTp-SP during ANC visits. However,
in light of the growing drug resistance to SP [37,38], its continued
use for IPTp may eventually be replaced by more effective
alternative drugs which may require alternative dosing schedules.
This study is potentially subject to the following types of bias and
limitations. Women who know IPTp is desirable and recommended
may be relatively more likely to falsely report taking SP for
prevention when they did not. However, based on the very high
concordance among self-reported SP and SP recorded on the ANC
card, the magnitude of this sort of social desirability bias is likely to
be minimal. Additionally, we did not have information on medical
contraindications to SP, such as history of sulfa drug allergies, or
daily use of cotrimoxazole for the prevention of HIV-associated
infections. If these factors were highly prevalent in our populations,
misclassification would lead to an overestimate of the prevalence of
missed opportunities, and the prevalence of appropriate SP use
would be underestimated. Furthermore, suspected malaria in this
area is treated presumptively, despite information which suggests
relatively few cases which present with malaria-like symptoms
actually have clinical malaria [39,40,41,42]. If a large proportion of
the women misclassified their reason for using SP, then our measure
of IPTp could be biased in either direction. Lastly, we were unable
to evaluate why health care providers failed to deliver IPTp for
apparently eligible women.
The strengths of this study included use of a population-based
random sample, validation of self-reported use of SP and ANC
visits through an assessment of the ANC cards, and use of several
visual aids throughout the interview to reduce recall bias. The
visual aids included a pregnancy history calendar in which each
pregnancy was mapped out over time on the calendar to record
episodes of self-reported malaria, any use of SP or other
antimalarials during pregnancy, and ANC visits, and photographs
of commercial packaging for the most common formulations of SP
available in the area, and the corresponding tablets.
In summary, we evaluated the level and determinants of use of
IPTp during pregnancy. Our results indicate that few women in
the Jinja district of Uganda were receiving the full 2-dose course of
IPTp according to the recommendations, and that women are
willing to take preventive SP in pregnancy if it is provided during
an ANC visit. Missed opportunities to administer SP during ANC
were common in our study, as was administration of SP in a
manner that is not directed by the Ugandan guidelines, suggesting
provider level improvements are needed. Improving healthcare
providers’ knowledge about the proper use and administration of
SP may be an effective intervention to improve uptake, as well as
simplifying the guidelines to provide IPTp-SP at each scheduled
ANC visit after quickening.
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